China’s Bio-Thera Solutions and Russia’s Pharmapark have added the Chinese firm’s BAT2306 proposed rival to Cosentyx (secukinumab) to an existing biosimilars licensing and supply agreement covering Russia and the Commonwealth of Independent States.
Bio-Thera And Pharmapark Add Cosentyx Rival To Russia-CIS Collaboration
Secukinumab Biosimilar Expands Deal That Already Includes Golimumab And Ustekinumab
China’s Bio-Thera Solutions and Russia’s Pharmapark have struck a deal to expand their existing biosimilars collaboration for Russia and the Commonwealth of Independent States with a further candidate: the Chinese firm’s BAT2306 proposed secukinumab biosimilar to Cosentyx.
More from Deals
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
• By
Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.
• By
Along with financial backing from the Canadian government, a fresh, decade-long partnership with Sandoz Canada will allow Delpharm to carry out modernization plans for its manufacturing facility in Boucherville, securing the local supply chain for sterile injectable medicines.
More from Business
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.
• By
With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.